ALDX Aldeyra Therapeutics (ALDX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001341235
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
53
13F, latest reported quarter
What the filings say about ALDX
Insiders, 180 days
+$417.5K net bought
1 buyer
Aldeyra Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Aldeyra Therapeutics, Inc. insiders bought a net $417.5K of stock across 34 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Mar 12, 2024.
- The trade is 14.5% of the 1,721,298 shares held after it.
- No other insider bought within 30 days.
- 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Brady Todd C bought about $417.5K of ALDX on Jun 3, 2026, the largest insider purchase at the company since 2024; 53 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 35.9% of the 195,000 shares held after it.
- 1 other insider bought within 30 days.
- 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DOUGLAS RICHARD bought about $98.0K of ALDX on Mar 19, 2026, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 53 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 13, 2025.
- The trade is 66.7% of the 7,500 shares held after it.
- 1 other insider bought within 30 days.
- 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Financial Officer Alfieri Michael bought about $7.1K of ALDX on Mar 18, 2026; 1 other insider bought within 30 days and 53 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 2,500 shares held after it.
- No other insider bought within 30 days.
- 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Principal Financial Officer Alfieri Michael bought about $13.2K of ALDX on Aug 13, 2025, the largest insider purchase at the company since 2024; 53 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 12, 2024.
- The trade is 10.0% of the 221,799 shares held after it.
- No other insider sold within 30 days.
- 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Machatha Stephen sold about $113.7K of ALDX on Aug 11, 2025; 53 funds added in the latest 13F quarter.34 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$417.5K over 180 days
more than 85% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
53 funds bought in last quarter
below 52% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.1% of the float short (float per yahoo 2026-10-26) · 3.0 days to cover · settled 2026-09-30
more than 54% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ALDX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-87.6%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALDX: institutional holders (13F)
13F holdings, latest reported quarter
5,475,516 sh
$11.7M
3,751,558 sh
$8.0M
2,652,315 sh
$5.6M
2,361,796 sh
$5.0M
1,940,338 sh
$4.1M
Congress trades in ALDX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ALDX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ALDX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AlphaCentric Life Sciences and Healthcare Fund
$80.2K position · as of 2026-06-30
0.2%
Invesco NASDAQ Future Gen 200 ETF
$24.6K position · as of 2026-05-31
0.1%
SMALL COMPANY GROWTH PORTFOLIO
$656.4K position · as of 2026-06-30
0.0%
PACE Small/Medium Co Growth Equity Investments
$80.5K position · as of 2026-07-31
0.0%
iShares Micro-Cap ETF
$399.4K position · as of 2026-06-30
0.0%
Clearwater Select Equity Fund
$88.9K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
34 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
17
Phase 2
0 active
13
Phase 3
1 active
4
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Todd C. Brady, M.D., Ph.D
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.7M
$4.3M
$848.2K
-26%
n/a
2024
$3.9M
$6.1M
$1.0M
-28%
n/a
2023
$3.7M
-$1.2M
$1.3M
-50%
n/a
2022
$2.9M
$10.6M
$2.0M
+74%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $417.5K bought by insiders over 180 days, 53 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ALDX financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ALDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ALDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$22.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ALDX
| FY Dec 2025 | -$33.3M |
| FY Dec 2024 | -$43.2M |
| FY Dec 2023 | -$30.3M |
| FY Dec 2022 | -$56.7M |
| FY Dec 2021 | -$42.6M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2026-03-31 plus current 2026-06-30; equity 2026-06-30
Debt to equity ALDX
| FY Dec 2025 | 0.34x |
| FY Dec 2024 | 0.21x |
| FY Dec 2023 | 0.13x |
| FY Dec 2022 | 0.10x |
| FY Dec 2021 | 0.08x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.36x |
| Dec 2025 | 0.34x |
| Sep 2025 | 0.31x |
| Jun 2025 | 0.27x |
| Mar 2025 | 0.24x |
| Dec 2024 | 0.21x |
| Sep 2024 | 0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt ALDX
| FY Dec 2025 | -2.19x |
| FY Dec 2024 | -2.87x |
| FY Dec 2023 | -2.00x |
| FY Dec 2022 | -3.58x |
| FY Dec 2021 | -2.66x |
| Jun 2026 | n/a |
| Mar 2026 | -1.70x |
| Dec 2025 | -2.19x |
| Sep 2025 | -2.64x |
| Jun 2025 | -2.71x |
| Mar 2025 | -3.03x |
| Dec 2024 | -2.87x |
| Sep 2024 | -2.01x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-49.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ALDX
| FY Dec 2025 | -58.7% |
| FY Dec 2024 | -58.5% |
| FY Dec 2023 | -27.7% |
| FY Dec 2022 | -34.8% |
| FY Dec 2021 | -43.6% |
| Jun 2026 | -49.5% |
| Mar 2026 | -51.8% |
| Dec 2025 | -58.7% |
| Sep 2025 | -64.3% |
| Jun 2025 | -65.9% |
| Mar 2025 | -65.2% |
| Dec 2024 | -58.5% |
| Sep 2024 | -43.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-34.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ALDX
| FY Dec 2025 | -38.3% |
| FY Dec 2024 | -44.2% |
| FY Dec 2023 | -22.8% |
| FY Dec 2022 | -29.9% |
| FY Dec 2021 | -36.5% |
| Jun 2026 | -34.8% |
| Mar 2026 | -34.3% |
| Dec 2025 | -38.3% |
| Sep 2025 | -44.3% |
| Jun 2025 | -48.0% |
| Mar 2025 | -49.2% |
| Dec 2024 | -44.2% |
| Sep 2024 | -33.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ALDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-51.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ALDX
| FY Dec 2025 | -54.1% |
| FY Dec 2024 | -56.7% |
| FY Dec 2023 | -29.3% |
| FY Dec 2022 | -32.4% |
| FY Dec 2021 | -38.5% |
| Jun 2026 | -51.6% |
| Mar 2026 | -46.9% |
| Dec 2025 | -54.1% |
| Sep 2025 | -60.4% |
| Jun 2025 | -69.3% |
| Mar 2025 | -61.6% |
| Dec 2024 | -56.7% |
| Sep 2024 | -44.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ALDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$31.4M
market value at close 2026-10-27 on 2026-08-04 shares, plus long-term 2026-03-31 plus current 2026-06-30, minus cash 2025-12-31
Enterprise value ALDX
| FY Dec 2025 | $256.9M |
| FY Dec 2024 | $257.7M |
| FY Dec 2023 | $77.2M |
| FY Dec 2022 | $279.0M |
| FY Dec 2021 | $18.5M |
| Jun 2026 | $58.4M |
| Mar 2026 | $47.0M |
| Dec 2025 | $256.9M |
| Sep 2025 | $268.5M |
| Jun 2025 | $203.3M |
| Mar 2025 | $308.1M |
| Dec 2024 | $257.7M |
| Sep 2024 | $267.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-56.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield ALDX
| FY Dec 2025 | -10.7% |
| FY Dec 2024 | -14.5% |
| FY Dec 2023 | -14.7% |
| FY Dec 2022 | -13.9% |
| FY Dec 2021 | -18.3% |
| Jun 2026 | -17.1% |
| Mar 2026 | -25.5% |
| Dec 2025 | -10.7% |
| Sep 2025 | -12.8% |
| Jun 2025 | -17.9% |
| Mar 2025 | -13.3% |
| Dec 2024 | -14.5% |
| Sep 2024 | -9.6% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ALDX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M |
| EPS (diluted) | -0.56 | -0.94 | -0.64 | -1.06 |
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M |
| Cash | $70.0M | $54.5M | n/a | $144.4M |
| Long-term debt | $0 | $15.0M | $0 | $14.9M |
SEC XBRL, fiscal years, as known on 2026-10-28
ALDX Stock Sonar score 5/7 axes
Find similar shapesCompareALDX ranks highest on financial health (99th percentile) and insider conviction (70th), and lowest on institutional and government (48th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ALDX filings, in plain words
Are Aldeyra Therapeutics insiders buying or selling ALDX?
In the 180 days to 2026-10-28, Aldeyra Therapeutics insiders were net buyers, a net $417.5K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Aldeyra Therapeutics insiders were net buyers of ALDX, a net $417.5K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
